OpGen Series B raises $5 million

Optical genome mapping company OpGen concluded the Series B round of funding for the company, raising a total of $5 million.

Register for free to listen to this article
Listen with Speechify
0:00
5:00
MADISON, Wis.— Optical genome mapping company OpGen concluded the Series B round of funding for the company, raising a total of $5 million. The money will be used to both create additional commercial optical whole genome maps the company sells to researchers, as well as for internal research aimed at developing a commercial optical mapping tool.
 
"The funding is important to our growth, as it lets us produce more optical maps to generate revenue right now, while furthering our other model as a provider of instrumentation," says Joe Shaw, CEO of OpGen.
 
The value of the company's optical maps is that they provide detailed genetic variation information inexpensively without the need for prior sequence information, Shaw says. Current customers for the optical maps run the gamut from large pharmaceutical and biotech companies to academic and independent research organizations.
 
"These sales provide important revenue for the company while we work to commercialize the tool," Shaw adds. "We think that we can have a tool and associated disposables on the market within the next two years. But we definitely have an advantage over many start-ups since we already have a solid revenue stream."


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue